It was recently shown that pancreatic cancer patients present circulating TEVs highly enriched in glypican-1 (GPC1) compared with healthy controls, this marker has been described to specifically correlate with early stage of pancreatic cancer [67]. This evidence concerns the gene GPC1 and pancreatic neoplasm.